Dss, INC Form 4 insider transactions

SEC Form 4 filing details transactions involving convertible promissory notes and warrants for DSS Inc., with reporting persons including directors and 10% owners.

DSS Inc. filed an amended Form 4 to correct its beneficial ownership of IMPACT BIOMEDICAL INC. common stock, now totaling 545,024 shares.

DSS Director and 10% owner, Heng Fai Ambrose Chan, sold 130,679 shares of common stock for approximately $1.35 per share under a Rule 10b5-1 trading plan.

DSS, Inc. filed an amended Form 4 to clarify details regarding a $500,000 convertible promissory note issued to Alset Inc., an entity controlled by Director Chan Heng Fai Ambrose.

DSS, Inc. issued a $500,000 convertible promissory note to Alset Inc., an entity controlled by director and 10% owner Chan Heng Fai Ambrose, convertible at $0.86 per share.

DSS, Inc., a 10% owner and director of IMPACT BIOMEDICAL INC., has reported the sale of its entire beneficial ownership of common stock in two transactions totaling 161,000 shares.

DSS, Inc. reports the sale of 890,800 shares of Impact Biomedical Inc. common stock at a price of $0.9486 per share on April 4, 2025.

DSS, Inc. reports the sale of Impact Biomedical Inc. common stock through a series of transactions, reducing its direct and indirect holdings.

DSS, Inc. reports transactions involving Impact Biomedical Inc. (IBO) common stock, including acquisitions and disposals, affecting its beneficial ownership.

Director Heng Fai Ambrose Chan receives a stock grant of 1,000,000 shares of DSS Inc. common stock as compensation for services.

DSS Inc.'s Executive Chairman, Heng Fai Ambrose Chan, and Alset Inc. have increased their holdings in the company through separate stock purchase agreements.

DSS, Inc. has reported the disposal of Impact Biomedical Inc. shares through a series of transactions, reducing its indirect holdings.

DSS, Inc. reports an increase in its indirect ownership of Impact Biomedical Inc. common stock through recent transactions and subsidiary holdings.

DSS, Inc., a 10% owner of Impact Biomedical Inc., reports acquiring additional shares of common stock through indirect ownership.